Pre-IND Development of an Arenavirus Antiviral
沙粒病毒抗病毒药物的 IND 前开发
基本信息
- 批准号:9914982
- 负责人:
- 金额:$ 100万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-02-10 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:ABCB1 geneABCG2 geneAcidsAfricaAnemiaAnimalsAntiviral AgentsArenavirusArenavirus InfectionsArgentinian Hemorrhagic FeverBinding ProteinsCanis familiarisCardiacCase Fatality RatesCategory A pathogenCaviaCell LineCellsChemicalsChemistryChinese Hamster Ovary CellChromosome abnormalityClinicalClinical PathologyCrystallizationDetectionDevelopmentDoseEngineeringEnzymesEquilibriumEvaluationExcipientsExcretory functionExhibitsFDA approvedFamilyFormulationG-Protein-Coupled ReceptorsGeographyGlycoproteinsGoalsHealthcare SystemsHigh Pressure Liquid ChromatographyHumanIn VitroInfectionIntestinesIon ChannelJunin virusLiquid substanceLiver ExtractManualsMaximum Tolerated DoseMethodsModelingMorbidity - disease rateNo-Observed-Adverse-Effect LevelOld World ArenavirusesOralOrganic solvent productOutcomeParticle SizePathogenicityPatientsPharmaceutical PreparationsPharmacologic SubstancePhasePhenotypePolymorphPreventive vaccineProcessRattusRecoveryRibavirinRunningSafetySeriesSerumSodium ChlorideSolidSolubilitySolventsStomachSurvivorsSuspensionsTabletsTestingTherapeuticTherapeutic IndexThrombocytopeniaTimeToxic effectToxicokineticsToxicologyTransplantationVaccinesVesicular stomatitis Indiana virusViral Hemorrhagic FeversVisualZoonosesanalytical methodaqueousbasecapsuledosageexperimental studyin vivoinfected vector rodentinhibitor/antagonistlead candidatemethod developmentmortalitynanomolarneurobehavioralnovelnovel therapeuticspatch clamppathogenpre-clinicalpreclinical studyprophylacticsafety studyscale upscreeningside effectsurfactanttransmission processweapons
项目摘要
Summary
Arenaviruses comprise a diverse family. Several species are associated with severe
arenaviral hemorrhagic fever (AVHF) in humans that exhibit case-fatality rates as high as
30%. Human infection with arenaviruses typically occurs through contact with materials
contaminated with the excretions of an infected rodent although direct human- to-human
transmission may occur in clinical settings. AVHF resulting from infection with the Old
World arenavirus Lassa is estimated to cause over 300,000 annual infections in Africa, of
which 15-20% of hospitalized patients die while survivors often suffer permanent
sequelae. Similar outcomes are observed with Argentine hemorrhagic fever (AHF), caused
by infection with Junin virus. A prophylactic vaccine has been developed against JUNV,
however, no vaccines are available against Lassa or the other human hemorrhagic fever
arenaviruses and broad-spectrum vaccines effective against both current and emerging
arenaviruses are unlikely to be developed. Ribavirin, the only available antiviral, can be
effective in treating arenavirus infection (particularly with IV administration in the first 6
days), however, there are serious side effects including thrombocytopenia and anemia. Given
the limited treatment and prophylactic options, the high mortality rate, the potential for
both zoonotic and human-to-human transmission, and the potential for geographical
transplantation and bio- weaponization six arenaviruses have been recognized as
Category A pathogens. W e have identified a novel chemical series of entry inhibitors including
drug-like candidate compounds with sub-nanomolar, broad spectrum arenavirus activity,
which exhibit remarkable in vivo efficacy. Here we propose Phase IIb studies to provide
IND-enabling studies of the lead candidate, including CMC, API process chemistry and scale up
as well as in vitro and in vivo toxicity and safety studies.
总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregory William Henkel其他文献
Gregory William Henkel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregory William Henkel', 18)}}的其他基金
IND-Enabling Studies for Arenavirus Preclinical Candidate
沙粒病毒临床前候选药物的 IND 启用研究
- 批准号:
10216086 - 财政年份:2021
- 资助金额:
$ 100万 - 项目类别:
IND-Enabling Studies for Arenavirus Preclinical Candidate
沙粒病毒临床前候选药物的 IND 启用研究
- 批准号:
10405034 - 财政年份:2021
- 资助金额:
$ 100万 - 项目类别:
IND-Enabling Studies for Arenavirus Preclinical Candidate
沙粒病毒临床前候选药物的 IND 启用研究
- 批准号:
10612905 - 财政年份:2021
- 资助金额:
$ 100万 - 项目类别:
Pre-IND Development of an Arenavirus Antiviral
沙粒病毒抗病毒药物的 IND 前开发
- 批准号:
10117166 - 财政年份:2014
- 资助金额:
$ 100万 - 项目类别:
Pre-IND Development of an Arenavirus Antiviral
沙粒病毒抗病毒药物的 IND 前开发
- 批准号:
10357791 - 财政年份:2014
- 资助金额:
$ 100万 - 项目类别: